CML has been treated with different types of TKI and JAK2-mutated MPN with various therapies, including hydroxyurea (HU), IFN, anagrelide, and ruxolitinib; however, an optimal management strategy has yet to be established due to the paucity of follow-up data. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.